REVIEW article
Front. Neurol.
Sec. Neurological Biomarkers
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1690767
Peripheral blood Immune inflammatory markers in neuromyelitis optica spectrum disorders
Provisionally accepted
- 1Zhejiang Chinese Medical University, Hangzhou, China
- 2The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
- 3Zhejiang Provincial People's Hospital, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune neuroinflammatory disease with high relapse risk and cumulative neurological disability. Identifying, providing early warning, and reproducible monitoring of disease progression and therapeutic efficacy in peripheral blood biomarkers is crucial for clinical management and personalized treatment. Numerous studies have investigated the relationship between peripheral blood immune-inflammatory markers including cytological ratios, cytokines, complement components and NMOSD disease activity, relapse risk, and long-term outcomes, aiming to evaluate their potential application in clinical prognostic assessment and treatment monitoring. Meta-analyses have shown that the neutrophil-to-lymphocyte ratio (NLR) is significantly elevated in patients with NMOSD compared with healthy controls (mean difference (MD) approximately 1.04, 95% CI 0.76–1.32; high heterogeneity). The NLR is associated with relapse risk and disability (EDSS ≥ 4) (OR for relapse, approximately 1.33–2.14; OR for EDSS ≥ 4, approximately 1.23–1.43), supporting the potential clinical application of peripheral blood Immune inflammatory markers in NMOSD. This review summarizes the current evidence for peripheral blood inflammatory markers in NMOSD, focusing on their clinical application.
Keywords: optica spectrum disorder, peripheral blood Immune inflammatory markers, Lymphocyte-to-monocyte ratio, Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio
Received: 22 Aug 2025; Accepted: 09 Oct 2025.
Copyright: © 2025 Wu, Xu, Cao, Gon and Mao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bin Xu, xubin2008.love@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.